Camacho F, Elorza F L, Ortega M, Elorza M A, Sada G, Villarrubia V G
Departamento de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Sevilla, España.
Rev Clin Esp. 1991 May;188(8):403-8.
In an open-controlled trial--oral washes (20 patients) versus test (19 patients)--, we have studied the effects of AM3 (a new oral BRM) on clinical evolution of the recurrent stomatitis (RAS) syndrome. The results obtained at 6th month showed significant decreases on ulcer numbers (p less than 0.001) as well as in their mean duration time (p less than 0.001) due to the AM3 treatment. From a pathophysiologic point of view, the study of the NK peripheral blood cells (Leu 11/CD16) suggests the existence of two kinds of RAS-patients: those showing normal NK cell numbers (approximately 33%) and those ones showing a partial lack in the NK numbers (approximately 67%). These results suggest different rational new approaches to treatment, based on new pathophysiological concepts.
在一项开放对照试验中（20例患者进行口腔冲洗，19例患者进行测试），我们研究了AM3（一种新型口服生物反应调节剂）对复发性口腔炎（RAS）综合征临床病程的影响。在第6个月获得的结果显示，由于AM3治疗，溃疡数量（p<0.001）及其平均持续时间（p<0.001）均显著减少。从病理生理学角度来看，对外周血自然杀伤细胞（Leu 11/CD16）的研究表明存在两种RAS患者：自然杀伤细胞数量正常的患者（约33%）和自然杀伤细胞数量部分缺乏的患者（约67%）。这些结果基于新的病理生理学概念，提示了不同的合理新治疗方法。
